Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V-ALERT Study of VTE incidence during amivantamab + lazertinib with apixaban prophylaxis in EGFR-mutant NSCLC
jRCTs071250140Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2026
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amivantamab, lazertinib and apixaban in non-small cell lung cancer (NSCLC) and venous thromboembolism (VTE), sponsored by Janssen Pharmaceutical. Started Apr 2026; status: recruiting.
02
Drugs
amivantamablazertinibapixaban
03
Conditions
non-small cell lung cancer (NSCLC)venous thromboembolism (VTE)
Beyond the preview
Go deeper on jRCTs071250140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071250140.